A carregar...

An Efficient Development Paradigm for Biosimilars

The current development paradigm for biosimilars required by regulators in highly regulated jurisdictions is derived from the development of novel drugs and is unnecessarily burdensome and inefficient. It requires the accumulation of data from analytical, nonclinical (including in vivo studies in so...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BioDrugs
Main Authors: Webster, Christopher J., Wong, Anny C., Woollett, Gillian R.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6875142/
https://ncbi.nlm.nih.gov/pubmed/31388969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-019-00371-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!